{"id":9952,"date":"2026-04-27T20:48:18","date_gmt":"2026-04-27T18:48:18","guid":{"rendered":"https:\/\/nexxusbio.com\/?p=9952"},"modified":"2026-09-07T17:04:48","modified_gmt":"2026-09-07T15:04:48","slug":"tb-500-peptid","status":"publish","type":"post","link":"https:\/\/nexxusbio.com\/en\/tb-500-peptid\/","title":{"rendered":"TB-500 Peptide \u226599% HPLC | Nexxus Bio"},"content":{"rendered":"
\n\t
\n\t\t
\n\t\t\t

Introduction \u2013 Why is TB-500 one of the most studied peptides in the world?<\/h2>\n

The world of peptide research has grown enormously in recent decades. Scientists worldwide are studying various biologically active molecules that play a key role in healing processes, tissue regeneration, and cellular communication. One of the most interesting and most studied peptides today is\u00a0TB-500<\/strong>, commonly also referred to as\u00a0Thymosin Beta-4 (T\u03b24)<\/strong>.<\/p>\n

This peptide has attracted the attention of researchers worldwide thanks to its unique mechanism of action and the wide range of biological activities observed in preclinical studies. Database\u00a0PubMed records more than 1,000 scientific articles<\/strong>\u00a0they are indexed under the term Thymosin Beta-4 \u2013 and their number is growing every year.<\/p>\n

In this article we will look at TB-500 from a purely\u00a0from a scientific and research perspective<\/strong>\u00a0\u2013 its structure, mechanism of action, results of studies in cell cultures and animal models, as well as the prospects for its future scientific investigation.<\/p>\n

\ud83d\udccc<\/em>\u00a0<\/em>Important notice:<\/em><\/strong>\u00a0All information in this article is purely of a research nature. TB-500 is not approved for human therapeutic use outside the framework of clinical studies. The article serves solely for educational and informational purposes in the field of scientific research.<\/em><\/p>\n

What is TB-500? History and origins<\/h2>\n

Thymosin Beta-4 was first isolated in the year\u00a01966<\/strong>\u00a0biochemist\u00a0By Allan Goldstein<\/strong>\u00a0from the thymus (the gland of the thymus) of cattle. The thymus is an organ of the immune system that plays a crucial role in the maturation of T-lymphocytes. Goldstein and his team originally studied a whole group of peptides called\u00a0thymine<\/strong>, While Thymosin Beta-4 later turned out to be one of the most biologically active representatives of this family.<\/p>\n

TB-500 is a synthetic version<\/strong>\u00a0in the active segment of endogenous Thymosin Beta-4. Specifically, it is a sequence of amino acids\u00a017 to 23<\/strong>\u00a0from the entire T\u03b24 chain \u2013 the so-called.\u00a0Active domain<\/strong>\u00a0responsible for most of the biological properties of the entire peptide. The naturally occurring Thymosin Beta-4 is\u00a043-amino acid polypeptide<\/strong>, which is present in mammals in practically all cells and tissues.<\/p>\n

An interesting fact is that T\u03b24 belongs to the\u00a0the most abundant intracellular peptides<\/strong>\u00a0Absolutely not. High concentrations were measured mainly in blood platelets, white blood cells, and various mesenchymal cells. This ubiquity indicates its fundamental role in cellular biology.<\/p>\n

Chemical structure and properties of TB-500<\/h2>\n

From a chemical perspective, TB-500 is a relatively small peptide with specific properties that allow for its biological activity:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
CHARACTERISTICS<\/strong><\/td>\nVALUE \/ DESCRIPTION<\/strong><\/td>\n<\/tr>\n
Chemical name<\/strong><\/td>\nThymosin Beta-4 (active fragment)<\/td>\n<\/tr>\n
Number of amino acids (TB-500)<\/strong><\/td>\n17 amino acids (T\u03b24 fragment)<\/td>\n<\/tr>\n
Number of amino acids (T\u03b24)<\/strong><\/td>\n43 amino acids<\/td>\n<\/tr>\n
Molecular weight<\/strong><\/td>\n~4 963 Da (T\u03b24)<\/td>\n<\/tr>\n
Solubility<\/strong><\/td>\nExcellently soluble in water<\/td>\n<\/tr>\n
Structure<\/strong><\/td>\nLinear peptide, without disulfide bonds<\/td>\n<\/tr>\n
Key domain<\/strong><\/td>\nActin-binding domain LKKTETQ<\/td>\n<\/tr>\n
Genes encoding T\u03b24<\/strong><\/td>\nTMSB4X (X-chromosome)<\/td>\n<\/tr>\n
Stability<\/strong><\/td>\nRelatively stable, sensitive to temperature changes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

One of the most important structural aspects of TB-500 is the presence of a sequence\u00a0LKKTETQ<\/strong>\u00a0\u2013 so-called.\u00a0actin-binding domain<\/strong>. It is this sequence that is responsible for the binding of the peptide to G-actin (globular actin) and influences the dynamics of the actin cytoskeleton \u2013 which has far-reaching consequences for cell motility and migration.<\/p>\n

Mechanism of action \u2013 How does TB-500 work at the cellular level?<\/h2>\n

Understanding the mechanism of action of TB-500 is the key to understanding why this peptide is so intensively studied. Scientists have identified several main molecular pathways:<\/p>\n

1. \ud83e\uddec Regulation of actin cytoskeleton<\/h3>\n

The best documented mechanism of TB-500 is its ability to\u00a0sequestrate G-actin<\/strong>\u00a0(monomeric actin). By binding to G-actin, TB-500 regulates the balance between the globular (G) and filamentous (F) actin in the cell. This regulation has a direct effect on:<\/p>\n

    \n
  • Bunker migration<\/strong>\u00a0\u2013 the cells can move more efficiently and navigate to the sites of injury<\/li>\n
  • Cellular proliferation<\/strong>\u00a0\u2013 Actin regulation affects cell division<\/li>\n
  • Morphology of cells<\/strong>\u00a0\u2013 shape and structural integrity of cells<\/li>\n<\/ul>\n

    Recent research (Keplinger et al., 2026,\u00a0J Biol Chem<\/em>) further clarify the complex interactions of actin-binding molecules including Thymosin Beta-4, thereby expanding our understanding of actin nuclear dynamics.<\/p>\n

    2. \ud83e\ude78 Angiogenesis \u2013 formation of new blood vessels<\/h3>\n

    TB-500 was identified in several preclinical studies as\u00a0proangiogenic factor<\/strong>. In research in mouse models, Thymosin Beta-4 stimulated the formation of new capillaries and blood vessels through:<\/p>\n

      \n
    • Activations\u00a0endothelial cells<\/strong><\/li>\n
    • Increased expression\u00a0VEGF (Vascular Endothelial Growth Factor)<\/strong><\/li>\n
    • Support for the formation of new vascular connections (anastomoses)<\/li>\n<\/ul>\n

      This property is of great interest from a research perspective, because angiogenesis is an essential step in tissue regeneration after injury or ischemic damage.<\/p>\n

      3. \ud83d\udee1\ufe0f Anti-inflammatory and immunomodulatory properties<\/h3>\n

      Several studies in cell cultures and animal models have demonstrated\u00a0modulation of the inflammatory response<\/strong>\u00a0after administration of T\u03b24. Specifically, the following was recorded:<\/p>\n

        \n
      • Reduced production\u00a0pro-inflammatory cytokines<\/strong>\u00a0(e.g., IL-1\u03b2, TNF-\u03b1)<\/li>\n
      • Increased production\u00a0anti-inflammatory mediators<\/strong><\/li>\n
      • Modulation of activity\u00a0NF-\u03baB signaling pathway<\/strong>\u00a0\u2013 key regulator of inflammatory processes<\/li>\n
      • Research by Sun et al. (2025) in\u00a0World Journal of Gastroenterology<\/em>\u00a0In addition, he documented the role of T\u03b24 released by the fat cells in regulating the intestinal barrier through\u00a0IL22RA1\/JAK1\/STAT3<\/strong>\u00a0signalling line<\/li>\n<\/ul>\n

        4. \ud83d\udd04 Activation of stem and progenitor cells<\/h3>\n

        Studies on cardiac models showed that Thymosin Beta-4 can\u00a0activate epicardial progenitor cells<\/strong>\u00a0\u2013 cells with the potential for differentiation into different types of heart cells, including cardiomyocytes and smooth muscle cells of the vessels.<\/p>\n

        5. \ud83d\udc8a Anti-apoptotic effects<\/h3>\n

        The ability of TB-500 was observed in models of oxidative stress and ischemia-reperfusion.\u00a0reduce cellular apoptosis<\/strong>\u00a0(programmed cell death) through:<\/p>\n

          \n
        • Activations\u00a0PI3K\/Akt signaling pathway<\/strong><\/li>\n
        • Decreases in expression of pro-apoptotic protein\u00a0Bax<\/strong><\/li>\n
        • Increases in the expression of the anti-apoptotic protein\u00a0Bcl-2<\/strong><\/li>\n<\/ul>\n

          6. \ud83e\udde0 Stabilization of the blood-brain barrier (BBB)<\/h3>\n

          A more recent study by Stewart et al. (2025,\u00a0Scientific Reports<\/em>) demonstrated that T\u03b24 stabilizes hypoxia-induced dysfunction in brain microvascular endothelial cells through\u00a0S1PR1-dependent mechanisms<\/strong>\u00a0\u2013 which opens up new possibilities for research into traumatic brain injuries (TBI) and cerebral ischemia.<\/p>\n

          Overview of key research areas<\/h2>\n

          \ud83e\udec0 Cardiovascular research<\/h3>\n

          Cardiology represents one of the most intensively studied areas in terms of potential use of Thymosin Beta-4. Breakthrough study\u00a0Zhang et al. (2025)<\/strong>\u00a0published in a prestigious journal\u00a0Cardiovascular Research<\/em>\u00a0demonstrated that recombinant human Thymosin Beta-4\u00a0improves ischemic heart dysfunction<\/strong>\u00a0Thus, in mouse models as well as in patients with acute ST-elevation myocardial infarction (STEMI) after reperfusion. This is one of the most significant cardiology research results in this field.<\/p>\n

          Other cardiology studies include:<\/strong><\/p>\n

            \n
          • Reduction of the size of the necrotic zone after a heart attack<\/li>\n
          • Improvement of the left ventricle ejection fraction<\/li>\n
          • Reduction of post-infarction fibrosis<\/li>\n
          • Activation of epicardial progenitor cells<\/li>\n<\/ul>\n

            \ud83e\udde0 Neurological research<\/h3>\n

            Neurodegenerative diseases:<\/strong>\u00a0A fundamental study\u00a0Ou et al. (2026)<\/strong>\u00a0v\u00a0International Immunopharmacology<\/em>\u00a0The therapeutic potential of peptides derived from Thymosin Beta-4 \u2013 including directly TB-500 and Ac-SDKP \u2013 was investigated in Alzheimer\u2019s disease. The results showed a reduction in neuroinflammation and neurite atrophy in both in vitro models and in 5xFAD mice.\u00a0in vivo<\/strong>\u00a0\u2013 which indicates the potential for improving memory.<\/p>\n

            Blood-brain barrier and TBI:<\/strong>\u00a0Stewart et al. (2025) document the protective function of T\u03b24 in hypoxia-induced damage to cerebral microvasculature via\u00a0S1PR1<\/strong>\u00a0receptor mechanism.<\/p>\n

            Spinal cord injuries:<\/strong>\u00a0Preclinical studies in rat models of spinal cord injury demonstrated improvement in neurological function, reduction of demyelination, and reduction of inflammatory infiltration at the site of injury.<\/p>\n

            \ud83e\uddb4 Research of the musculoskeletal system and the locomotor system<\/h3>\n

            Overview study\u00a0Mendias & Awan (2026)<\/strong>\u00a0v\u00a0Sports Medicine<\/em>\u00a0It specifically focuses on the pharmacological mechanisms, safety profile, and regulatory status of peptides \u2013 including TB-500 \u2013 in the context of musculoskeletal injuries. This is the most comprehensive current scientific review in this field.<\/p>\n

            Muscles and ligaments:<\/strong>\u00a0Studies on animal models of tendon injuries showed accelerated tendon regeneration and improved biomechanical strength of the regenerated tissue.<\/p>\n

            Muscles:<\/strong>\u00a0In models of muscular dystrophy (MDX mice) and acute muscle injuries, a reduction in fibrosis, increased regeneration of muscle fibers, and activation of satellite cells were observed.<\/p>\n

            \ud83d\udc41\ufe0f Ophthalmological research<\/h3>\n

            This area represents one of the most clinically proven directions of T\u03b24 research:<\/p>\n

            Cornea healing:<\/strong>\u00a0Study\u00a0Nguyen et al. (2025)<\/strong>\u00a0v\u00a0Investigative Ophthalmology & Visual Science<\/em>\u00a0focuses on engineered tandem thymosin peptides to overcome the limitations of natural Thymosin Beta-4 \u2013 short biological half-life and cost of synthesis \u2013 while maintaining its beneficial effect on corneal healing.<\/p>\n

            Dry eye (DED):<\/strong>\u00a0The company\u00a0RegeneRx Biopharmaceuticals<\/strong>\u00a0It conducted Phase II clinical study with locally applied T\u03b24 (RGN-259) in dry eye syndrome with proven positive results.<\/p>\n

            \ud83e\ude7a Nephrological research \u2013 a new research direction<\/h3>\n

            One of the newest and most promising areas of research is nephrology. A review study\u00a0Di et al. (2026)<\/strong>\u00a0published in a journal\u00a0Peptides<\/em>\u00a0Identifies Thymosin Beta-4 as\u00a0emerging therapeutic candidate for kidney diseases<\/strong>, While emphasizing its evolutionary conservatism (the TMSB4X gene), and its multi-organ protective potential.<\/p>\n

            \ud83d\udd2c Oncological research<\/h3>\n

            Recent proteomic study\u00a0Simiczyjew et al. (2026)<\/strong>\u00a0v\u00a0Journal of Proteome Research<\/em>\u00a0They identified Thymosin Beta-4 as one of the proteins increased in secretion by resistant melanoma cells compared to control cells \u2013 indicating its potential role as a biomarker or therapeutic target in melanoma. However, this area is controversial and requires further research.<\/p>\n

            Study\u00a0Guo et al. (2025)<\/strong>\u00a0v\u00a0Medical Oncology<\/em>\u00a0In addition, it was shown that the T\u03b24-17 fragment increases the chemosenitivity of ovarian cancer cells to cisplatin through modulation.\u00a0NF-\u03baB signaling pathway<\/strong>\u00a0\u2013 which opens up interesting perspectives in oncology research.<\/p>\n

            Veterinary research \u2013 TB-500 in horses and dogs<\/h2>\n

            An interesting chapter in the history of TB-500 research is its study of its effects on the\u00a0veterinary medicine<\/strong>. Thymosin Beta-4 was tested in horses in the context of:<\/p>\n

              \n
            • Tendinopathy<\/strong>\u00a0\u2013 tendon injuries are a common and serious problem in racehorses<\/li>\n
            • Damaged ligaments<\/strong>\u00a0\u2013 suspended sentence and other structures<\/li>\n
            • Musculoskeletal injuries<\/strong>\u00a0in general<\/li>\n<\/ul>\n

              Research results in horses indicated a potential improvement in the histological quality of regenerated muscle tissue and a shortening of the recovery time compared to control groups. In dogs, the research focused primarily on injuries to joints, ligaments, and neurological conditions.<\/p>\n

              Pharmacokinetics and distribution research<\/h2>\n

              From a pharmacological research perspective, it is important to understand how TB-500 behaves after administration:<\/p>\n

              Biological availability:<\/strong>\u00a0Studies in animal models have shown that TB-500 has the ability to distribute into various tissues after systemic administration, with increased accumulation observed at sites of injury.<\/p>\n

              Halfway through the breakup:<\/strong>\u00a0Studies suggest a relatively short biological half-life of the peptide. This limiting factor is precisely the subject of research into new engineering approaches \u2013 for example, Nguyen et al. (2025) are working on tandem peptide constructs with extended stability.<\/p>\n

              Metabolism:<\/strong>\u00a0As a peptide, TB-500 is degraded by proteases into individual amino acids, which are recycled within normal metabolism.<\/p>\n

              Safety profile \u2013 what does the research say?<\/h2>\n\n\n\n\n\n\n\n\n\n
              ASPEKT<\/strong><\/td>\nFINDINGS OF THE STUDY<\/strong><\/td>\n<\/tr>\n
              Acute toxicity<\/strong><\/td>\nNot demonstrated in standard preclinical models at tested doses<\/td>\n<\/tr>\n
              Genotoxicity \/ mutagenicity<\/strong><\/td>\nNot proven in standard tests<\/td>\n<\/tr>\n
              Local tolerance<\/strong><\/td>\nGood for local application (RegeneRx clinical studies)<\/td>\n<\/tr>\n
              Oncological risk<\/strong><\/td>\nSubject of further research (increased expression in some tumors)<\/td>\n<\/tr>\n
              Regulatory status<\/strong><\/td>\nNot approved for human therapy outside clinical studies<\/td>\n<\/tr>\n
              WADA status<\/strong><\/td>\nListed on the list of prohibited substances in sports<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

              TB-500 vs. BPC-157 \u2013 Comparison of the research profile<\/h2>\n

              In the field of research into regenerative peptides, TB-500 is often mentioned in the context of\u00a0BPC-157<\/strong>\u00a0(Body Protection Compound 157). Although both peptides are subject to intensive preclinical research, they have different mechanisms of action:<\/p>\n\n\n\n\n\n\n\n\n\n\n
              CHARACTERISTICS<\/strong><\/td>\nTB-500 (THYMOSIN BETA-4)<\/strong><\/td>\nBPC-157<\/strong><\/td>\n<\/tr>\n
              Origin<\/strong><\/td>\nEndogenous (thymus, TMSB4X gene)<\/td>\nDerived from gastric juice<\/td>\n<\/tr>\n
              Number of amino acids<\/strong><\/td>\n17 (fragment) \/ 43 (T\u03b24)<\/td>\n15<\/td>\n<\/tr>\n
              The main mechanism<\/strong><\/td>\nActin regulation, angiogenesis, S1PR1<\/td>\nModulation of the NO system, angiogenesis<\/td>\n<\/tr>\n
              Main research areas<\/strong><\/td>\nHeart, neurology, tendons, eye, kidneys<\/td>\nGIT, tendons, bones, neurology<\/td>\n<\/tr>\n
              Clinical trials<\/strong><\/td>\nYes (RegeneRx \u2013 ophthalmology, wounds)<\/td>\nLimited clinical data<\/td>\n<\/tr>\n
              Regulatory status<\/strong><\/td>\nNot approved for therapy (outside of clinical studies)<\/td>\nNot approved for therapy<\/td>\n<\/tr>\n
              Number of PubMed publications<\/strong><\/td>\n>1 000<\/td>\n>300<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

              Genomic expression, proteomics and epigenetics<\/h2>\n

              Advanced research methods such as transcriptomics (RNA-seq), proteomics, and epigenetic analysis have revealed that Thymosin Beta-4 influences the expression of a wide range of genes. Among the most significant are:<\/p>\n